Published in Blood Cells Mol Dis on September 13, 2005
Fetal globin gene inducers: novel agents and new potential. Ann N Y Acad Sci (2010) 0.95
A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. Br J Haematol (2013) 0.93
Erythroid Kruppel-like factor (EKLF) is recruited to the gamma-globin gene promoter as a co-activator and is required for gamma-globin gene induction by short-chain fatty acid derivatives. Eur J Haematol (2009) 0.93
Butyrate histone deacetylase inhibitors. Biores Open Access (2012) 0.90
Novel therapeutic candidates, identified by molecular modeling, induce γ-globin gene expression in vivo. Blood Cells Mol Dis (2011) 0.85
Short-chain fatty acid-mediated effects on erythropoiesis in primary definitive erythroid cells. Blood (2009) 0.83
A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease. Am J Hematol (2012) 0.83
Evaluation of safety and pharmacokinetics of sodium 2,2 dimethylbutyrate, a novel short chain fatty acid derivative, in a phase 1, double-blind, placebo-controlled, single-dose, and repeat-dose studies in healthy volunteers. J Clin Pharmacol (2011) 0.81
Liquid chromatography-mass spectrometric assay for quantitation of the short-chain fatty acid, 2,2-dimethylbutyrate (NSC 741804), in rat plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 0.81
A phase 2 trial of HQK-1001 in HbE-β thalassemia demonstrates HbF induction and reduced anemia. Blood (2014) 0.78
Therapeutic fetal-globin inducers reduce transcriptional repression in hemoglobinopathy erythroid progenitors through distinct mechanisms. Blood Cells Mol Dis (2015) 0.75
Potential anti-genotoxic effect of sodium butyrate to modulate induction of DNA damage by tamoxifen citrate in rat bone marrow cells. Cytotechnology (2016) 0.75
Serum Bcl-2 Levels in Patients with β-Thalassemia Minor: A Pilot Study. Turk J Haematol (2014) 0.75
BCL-2 family: regulators of cell death. Annu Rev Immunol (1998) 6.41
Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts. Blood (2001) 6.35
Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J Cell Physiol (1989) 3.89
Apoptosis in the development and maintenance of the immune system. Nat Immunol (2003) 3.02
Tumorigenicity of cells transformed by adenovirus type 12 by evasion of T-cell immunity. Nature (1983) 2.96
Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial. Blood (1995) 2.82
Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood (1999) 2.66
Accelerated programmed cell death (apoptosis) in erythroid precursors of patients with severe beta-thalassemia (Cooley's anemia) Blood (1993) 1.93
Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N Engl J Med (1998) 1.85
New insights into erythropoiesis. Curr Opin Hematol (2002) 1.69
Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood (1996) 1.68
Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines. J Biol Chem (1999) 1.64
The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with beta-thalassemia major. Blood (2000) 1.49
Brief report: treatment with azacitidine of patients with end-stage beta-thalassemia. N Engl J Med (1993) 1.48
The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood (2000) 1.46
A correlation of erythrokinetics, ineffective erythropoiesis, and erythroid precursor apoptosis in thai patients with thalassemia. Blood (2000) 1.44
Butyrate-induced G1 arrest results from p21-independent disruption of retinoblastoma protein-mediated signals. Cell Growth Differ (1998) 1.28
Alterations in protein-DNA interactions in the gamma-globin gene promoter in response to butyrate therapy. Blood (1998) 1.24
Pharmacologic modulation of fetal hemoglobin. Medicine (Baltimore) (2001) 1.23
Short-chain fatty acid derivatives stimulate cell proliferation and induce STAT-5 activation. Blood (2001) 1.19
Activation of extracellular signal-regulated kinases ERK1 and ERK2 induces Bcl-xL up-regulation via inhibition of caspase activities in erythropoietin signaling. J Cell Physiol (2003) 1.12
alpha-Amino butyric acid cannot reactivate the silenced gamma gene of the beta locus YAC transgenic mouse. Blood (1994) 1.08
Oral isobutyramide therapy in patients with thalassemia intermedia: results of a phase II open study. Blood Cells Mol Dis (2000) 1.06
A mechanistic approach to anticancer therapy: targeting the cell cycle with histone deacetylase inhibitors. Curr Pharm Des (2005) 1.04
Pharmacologic treatment of thalassemia intermedia with hydroxyurea. J Pediatr (1994) 1.02
Novel cis-acting elements in the human platelet-derived growth factor B-chain core promoter that mediate gene expression in cultured vascular endothelial cells. J Biol Chem (1994) 0.99
Treatment of thalassaemia major with phenylbutyrate and hydroxyurea. Lancet (1997) 0.94
Pathobiology of thalassemic erythrocytes. Curr Opin Hematol (1997) 0.92
Differential expression of bcl-2 homologs in human CD34(+) hematopoietic progenitor cells induced to differentiate into erythroid or granulocytic cells. Stem Cells (2000) 0.90
Histone deacetylase inhibition-mediated post-translational elevation of p27KIP1 protein levels is required for G1 arrest in fibroblasts. J Cell Physiol (2005) 0.90
5-Azacytidine treatment in a beta (0)-thalassaemic patient unable to be transfused due to multiple alloantibodies. Br J Haematol (1989) 0.89
The function of the bcl-x promoter in erythroid progenitor cells. Blood (2002) 0.87
Inhibition of estrogen-dependent breast cell responses with phenylacetate. Int J Cancer (2001) 0.87
Advances in experimental treatment of beta-thalassaemia. Expert Opin Investig Drugs (2001) 0.86
Stem cell factor protects erythroid precursor cells from chemotherapeutic agents via up-regulation of BCL-2 family proteins. Blood (2003) 0.85
Selection with a regulated cell growth switch increases the likelihood of expression for a linked gamma-globin gene. Blood Cells Mol Dis (2005) 0.81
The signaling pathways of erythropoietin and interferon-gamma differ in preventing the apoptosis of mature erythroid progenitor cells. Int J Hematol (2003) 0.77
Identification of transcription complexes that contain the double bromodomain protein Brd2 and chromatin remodeling machines. J Proteome Res (2006) 1.64
A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood (2006) 1.57
Sickle cell anemia is associated with reduced nitric oxide bioactivity in peripheral conduit and resistance vessels. Am J Hematol (2003) 1.53
E mu-BRD2 transgenic mice develop B-cell lymphoma and leukemia. Blood (2003) 1.51
Sirtuin 1 is required for antagonist-induced transcriptional repression of androgen-responsive genes by the androgen receptor. Mol Endocrinol (2007) 1.43
Retracted HIC1 regulates tumor cell responses to endocrine therapies. Mol Endocrinol (2009) 1.42
Bromodomain analysis of Brd2-dependent transcriptional activation of cyclin A. Biochem J (2005) 1.38
Prohibitin requires Brg-1 and Brm for the repression of E2F and cell growth. EMBO J (2002) 1.34
BRG1/BRM and prohibitin are required for growth suppression by estrogen antagonists. EMBO J (2004) 1.29
Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo. Blood (2002) 1.26
Aberrant cytoplasm localization and protein stability of SIRT1 is regulated by PI3K/IGF-1R signaling in human cancer cells. Int J Biol Sci (2010) 1.24
Histone deacetylase inhibitors reverse CpG methylation by regulating DNMT1 through ERK signaling. Anticancer Res (2011) 1.15
Short-chain fatty acids induce gamma-globin gene expression by displacement of a HDAC3-NCoR repressor complex. Blood (2006) 1.15
Prohibitin and the SWI/SNF ATPase subunit BRG1 are required for effective androgen antagonist-mediated transcriptional repression of androgen receptor-regulated genes. Carcinogenesis (2008) 1.12
Short-chain fatty acid inhibitors of histone deacetylases: promising anticancer therapeutics? Curr Cancer Drug Targets (2003) 1.10
Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents. Blood (2011) 1.09
Telomere homolog oligonucleotides induce apoptosis in malignant but not in normal lymphoid cells: mechanism and therapeutic potential. Int J Cancer (2009) 1.08
Tumor-specific and proliferation-specific gene expression typifies murine transgenic B cell lymphomagenesis. J Biol Chem (2006) 1.08
Medical hyperspectral imaging to facilitate residual tumor identification during surgery. Cancer Biol Ther (2007) 1.05
Bcl-2, via its BH4 domain, blocks apoptotic signaling mediated by mitochondrial Ras. J Biol Chem (2002) 1.05
Tritrichomonas foetus from domestic cats and cattle are genetically distinct. Exp Parasitol (2010) 1.05
The cat flea (Ctenocephalides f. felis) is the dominant flea on domestic dogs and cats in Australian veterinary practices. Vet Parasitol (2011) 1.04
Protein kinase C delta is required for survival of cells expressing activated p21RAS. J Biol Chem (2007) 1.04
Carcinogen-induced S-phase arrest is Chk1 mediated and caffeine sensitive. Cell Growth Differ (2002) 1.03
Targeting the RAS oncogene. Expert Opin Ther Targets (2013) 1.02
SIRT1 enhances matrix metalloproteinase-2 expression and tumor cell invasion in prostate cancer cells. Prostate (2012) 1.00
SIRT1 represses estrogen-signaling, ligand-independent ERα-mediated transcription, and cell proliferation in estrogen-responsive breast cells. J Endocrinol (2013) 0.98
Protein kinase Cδ inactivation inhibits cellular proliferation and decreases survival in human neuroendocrine tumors. Endocr Relat Cancer (2011) 0.97
Induction of fetal globin in beta-thalassemia: Cellular obstacles and molecular progress. Ann N Y Acad Sci (2005) 0.96
Haemonchus contortus infection in sheep: parasite fecundity correlates with worm size and host lymphocyte counts. Vet Parasitol (2008) 0.96
Fetal globin gene inducers: novel agents and new potential. Ann N Y Acad Sci (2010) 0.95
Development of a malignancy-associated proteomic signature for diffuse large B-cell lymphoma. Am J Pathol (2009) 0.94
A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. Br J Haematol (2013) 0.93
Transcription Regulation by Class III Histone Deacetylases (HDACs)-Sirtuins. Transl Oncogenomics (2008) 0.93
Erythroid Kruppel-like factor (EKLF) is recruited to the gamma-globin gene promoter as a co-activator and is required for gamma-globin gene induction by short-chain fatty acid derivatives. Eur J Haematol (2009) 0.93
Drosophila female sterile (1) homeotic is a multifunctional transcriptional regulator that is modulated by Ras signaling. Dev Dyn (2008) 0.91
Epstein-Barr virus latent membrane protein-1 induction by histone deacetylase inhibitors mediates induction of intercellular adhesion molecule-1 expression and homotypic aggregation. Virology (2002) 0.91
Loss of putative tumor suppressor EI24/PIG8 confers resistance to etoposide. FEBS Lett (2007) 0.91
Telomerase inhibitors and 'T-oligo' as cancer therapeutics: contrasting molecular mechanisms of cytotoxicity. Anticancer Drugs (2008) 0.90
Histone deacetylase inhibition-mediated post-translational elevation of p27KIP1 protein levels is required for G1 arrest in fibroblasts. J Cell Physiol (2005) 0.90
Aberrant activation of gamma-catenin promotes genomic instability and oncogenic effects during tumor progression. Cancer Biol Ther (2007) 0.90
Butyrate histone deacetylase inhibitors. Biores Open Access (2012) 0.90
Advances in Virus-Directed Therapeutics against Epstein-Barr Virus-Associated Malignancies. Adv Virol (2012) 0.89
T-oligos inhibit growth and induce apoptosis in human ovarian cancer cells. Oligonucleotides (2011) 0.89
PKCdelta survival signaling in cells containing an activated p21Ras protein requires PDK1. Cell Signal (2008) 0.89
Experimental infection model for Johne's disease using a lyophilised, pure culture, seedstock of Mycobacterium avium subspecies paratuberculosis. Vet Microbiol (2009) 0.88
Alpha-lipoic acid induces p27Kip-dependent cell cycle arrest in non-transformed cell lines and apoptosis in tumor cell lines. J Cell Physiol (2003) 0.87
A randomized phase II trial of Arginine Butyrate with standard local therapy in refractory sickle cell leg ulcers. Br J Haematol (2010) 0.87
Identification of novel small-molecule inducers of fetal hemoglobin using pharmacophore and 'PSEUDO' receptor models. Chem Biol Drug Des (2006) 0.86
Mechanism of T-oligo-induced cell cycle arrest in Mia-PaCa pancreatic cancer cells. J Cell Physiol (2012) 0.86
Novel therapeutic candidates, identified by molecular modeling, induce γ-globin gene expression in vivo. Blood Cells Mol Dis (2011) 0.85
Mutations that abrogate transactivational activity of the feline leukemia virus long terminal repeat do not affect virus replication. Virology (2003) 0.84
A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. Am J Hematol (2013) 0.84
Management of unstable slipped upper femoral epiphysis: a meta-analysis. Br Med Bull (2009) 0.84
Leukemia virus long terminal repeat activates NFkappaB pathway by a TLR3-dependent mechanism. Virology (2005) 0.83
A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease. Am J Hematol (2012) 0.83
A vitamin D receptor-alkylating derivative of 1α,25-dihydroxyvitamin D3 inhibits growth of human kidney cancer cells and suppresses tumor growth. Cancer Prev Res (Phila) (2010) 0.83
Short, discontinuous exposure to butyrate effectively sensitizes latently EBV-infected lymphoma cells to nucleoside analogue antiviral agents. Blood Cells Mol Dis (2006) 0.82
Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part I. In vivo studies. Leuk Res (2004) 0.82
Novel short chain fatty acids restore chloride secretion in cystic fibrosis. Biochem Biophys Res Commun (2006) 0.82
Liquid chromatography-mass spectrometric assay for quantitation of the short-chain fatty acid, 2,2-dimethylbutyrate (NSC 741804), in rat plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 0.81
Evaluation of safety and pharmacokinetics of sodium 2,2 dimethylbutyrate, a novel short chain fatty acid derivative, in a phase 1, double-blind, placebo-controlled, single-dose, and repeat-dose studies in healthy volunteers. J Clin Pharmacol (2011) 0.81
Desensitization of the PDGFbeta receptor by modulation of the cytoskeleton: the role of p21(Ras) and Rho family GTPases. Exp Cell Res (2002) 0.81
Characterization of p21Ras-mediated apoptosis induced by protein kinase C inhibition and application to human tumor cell lines. J Cell Physiol (2004) 0.80
Identification of LTR-specific small non-coding RNA in FeLV infected cells. FEBS Lett (2009) 0.80
Protein kinase Cδ is a therapeutic target in malignant melanoma with NRAS mutation. ACS Chem Biol (2014) 0.79
Enhanced cytotoxicity from deoxyguanosine-enriched T-oligo in prostate cancer cells. Nucleic Acid Ther (2013) 0.79
Roles of prohibitin in growth control and tumor suppression in human cancers. Transl Oncogenomics (2008) 0.78
A phase 2 trial of HQK-1001 in HbE-β thalassemia demonstrates HbF induction and reduced anemia. Blood (2014) 0.78
Effects of divalproex sodium on hemoglobin level. Blood Cells Mol Dis (2009) 0.78
Telomere-homologous G-rich oligonucleotides sensitize human ovarian cancer cells to TRAIL-induced growth inhibition and apoptosis. Nucleic Acid Ther (2013) 0.78
The role of Ras in T lymphocyte activation. Cell Signal (2002) 0.78
Fas ligand-mediated lethal hepatitis after rapid lysis of a localized natural killer cell lymphoma. Clin Lymphoma Myeloma (2006) 0.78
A phase 2 study of HQK-1001, an oral fetal haemoglobin inducer, in β-thalassaemia intermedia. Br J Haematol (2013) 0.77
Prostate 25-hydroxyvitamin D-1alpha-hydroxylase is up-regulated by suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor. Anticancer Res (2008) 0.77
Biochemical effect of intravenous arginine butyrate in X-linked adrenoleukodystrophy. J Pediatr (2003) 0.77
Apoptosis of lymph node and peripheral blood cells in ovine Johne's disease. Vet Immunol Immunopathol (2013) 0.76
Short-term toxicity study of ST-20 (NSC-741804) by oral gavage in Sprague-Dawley rats. Toxicol Pathol (2011) 0.75
Differential effects of short-chain fatty acids on head and neck squamous carcinoma cells. Laryngoscope (2002) 0.75